- Home
- HSIC vs LEGN Comparison
HSIC vs LEGN Comparison
Compare HSIC & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSIC
- LEGN
- Stock Information
- Founded
- HSIC 1932
- LEGN 2014
- Country
- HSIC United States
- LEGN United States
- Employees
- HSIC N/A
- LEGN N/A
- Industry
- HSIC Medical Specialities
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- HSIC Health Care
- LEGN Health Care
- Exchange
- HSIC Nasdaq
- LEGN Nasdaq
- Market Cap
- HSIC 9.0B
- LEGN 5.4B
- IPO Year
- HSIC 1995
- LEGN 2020
- Fundamental
- Price
- HSIC $71.09
- LEGN $39.34
- Analyst Decision
- HSIC Buy
- LEGN Strong Buy
- Analyst Count
- HSIC 10
- LEGN 12
- Target Price
- HSIC $79.70
- LEGN $73.91
- AVG Volume (30 Days)
- HSIC 1.6M
- LEGN 1.6M
- Earning Date
- HSIC 08-05-2025
- LEGN 08-08-2025
- Dividend Yield
- HSIC N/A
- LEGN N/A
- EPS Growth
- HSIC 8.11
- LEGN N/A
- EPS
- HSIC 3.21
- LEGN N/A
- Revenue
- HSIC $12,669,000,000.00
- LEGN $728,303,000.00
- Revenue This Year
- HSIC $4.28
- LEGN $65.49
- Revenue Next Year
- HSIC $3.57
- LEGN $53.76
- P/E Ratio
- HSIC $22.88
- LEGN N/A
- Revenue Growth
- HSIC 1.75
- LEGN 112.46
- 52 Week Low
- HSIC $60.56
- LEGN $27.34
- 52 Week High
- HSIC $82.49
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- HSIC 55.47
- LEGN 66.83
- Support Level
- HSIC $73.02
- LEGN $38.86
- Resistance Level
- HSIC $75.76
- LEGN $39.88
- Average True Range (ATR)
- HSIC 1.36
- LEGN 1.41
- MACD
- HSIC -0.01
- LEGN 0.34
- Stochastic Oscillator
- HSIC 52.24
- LEGN 90.21
About HSIC Henry Schein Inc.
Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services to office-based dental and medical practitioners, as well as alternate sites of care. The company's reportable segments are global Distribution and Value-Added Services; global Specialty Products; and global Technology. It generates the majority of its revenue from the global Distribution and Value-Added Services segment which includes distribution to the global dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.